Skip to main content

Free Content A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design

Download Article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary

Phase-III vaccine efficacy trials typically employ individually randomized designs intended to ensure that measurements of vaccine protective efficacy reflect only direct vaccine effects. As a result, decisions about introducing newly licensed vaccines into public health programmes often fail to consider the substantially greater protection that may occur when a vaccine is deployed in public health programmes, due to the combination of direct plus indirect vaccine protective effects. Vaccine total protection can be better evaluated with cluster randomized trials. Such a design was considered to generate policy relevant data to accelerate the rationale introduction of the licensed typhoid fever Vi polysaccharide (PS) vaccine in Asia by the Diseases of the Most Impoverished (DOMI) typhoid fever programme. The DOMI's programme multi-country study is one of the largest cluster randomized vaccine trials ever mounted in Asia, which includes approximately 200 000 individuals. Its main objective is to determine the effectiveness of a licensed Vi PS vaccine. The rationale and design of this study are discussed. Preliminary results are presented that determined the final planning of the trial before immunization. Important methodological and practical issues regarding vaccine cluster randomized designs are illustrated.

Keywords: Vi polysaccharide vaccine; effectiveness trial; typhoid fever

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1365-3156.2005.01517.x

Affiliations: 1: International Vaccine Institute, Seoul, South Korea 2: National Institute of Hygiene and Epidemiology, Hanoi, Vietnam 3: Guangxi Center for Disease Prevention and Control, Nanning, Guangxi, China 4: National Institute of Health Research and Development, Ministry of Health Republic of Indonesia, Indonesia 5: NAMRU-2, Jakarta, Indonesia 6: National Institute of Cholera and Enteric Diseases, Kolkata, India 7: Aga Khan University, Karachi, Pakistan 8: Research Policy and Cooperation, World Health Organization, Geneva, Switzerland 9: University of Western Ontario, Ont., Canada

Publication date: December 1, 2005

bsc/tmih/2005/00000010/00000012/art00003
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more